Allergic disease may affect as many as 50 million Americans, and most people with allergies are likely to have an ocular component.
This is an expert panel discussion on ocular allergy classification and diagnosis, as well as a review of current and future treatments. The faculty also discuss the correlation between dry eye disease and ocular allergy.
Supported by an unrestricted educational grant from Ocular Therapeutix.
Upon completion of this activity, the participant should be able to:
This educational activity is provided by Evolve Medical Education LLC (Evolve).
Accreditation Statement
Evolve is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statements
Evolve designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Sponsored by:
Evolve Medical Education LLC (Evolve) is a COPE Accredited administrator.
This activity, COPE Activity Number 123592, is accredited by COPE for continuing education for optometrists for 1.25 hours.
Course #: 77501-TD
Activity #: 123592
In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.
John A. Hovanesian, MD
Clinical Instructor
Jules Stein Eye Institute
University of California Los Angeles
Owner
Harvard Eye Associates
Laguna Hills, CA
Preeya K. Gupta, MD
Managing Director
Triangle Eye Consultants
Cary, NC
Mitch Ibach, OD, FAAO
Cataract, Cornea, Refractive, and Glaucoma Surgery Specialist
Vance Thompson Vision
Sioux Falls, SD
DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all financial relationships prior to this educational activity.
The following faculty/staff members have the following financial relationships with ineligible companies.
John A. Hovanesian, MD, has had a financial agreement or affiliation with the following ineligible companies in the form of Consultant: 1-800-DOCTORS, Abbott Medical Optics, Acufocus, Aerie Pharmaceuticals, Alcon, Allegro Ophthalmics, Allergan, BlephEx, Eyedetec, Glaukos, Guardion Health Sciences, IOP/Katena, Ivantis, Kala Pharmaceuticals, Novartis, Ocular Therapeutix, Omeros, ReVision Optics, Sarentis Ophthalmics, Sensimed, Shire, Tear Film Innovations, TearLab, Valeant, Veracity, and Vindico Medical Education. Advisory Board: 1-800-DOCTORS, Abbott Medical Optics, Aerie Pharmaceutical, BlephEx, Cord LLC, Eyedetec, Glaukos, Guardion Health Sciences, Ingenoeye, IOP/Katena, Ivantis, Kala Pharmaceuticals, MDbackline, Ocular Therapeutix, Omeros, ReVision Optics, Shire, Sight Sciences, Tear Film Innovations, TearLab, Valeant, and Veracity. Grant/Research Support: Abbott Medical Optics, Acufocus, Aerie Pharmaceutical, Alcon, Cloudbreak Therapeutics, Cord, Eyedetec, Glaukos, Ingenoeye, IOP/Katena, Novartis, Ocular Therapeutix, Omeros, ReVision Optics, Shire, Tear Film Innovations, and Valeant. Stock/Shareholder: Alcon, Alicia Surgery Center, Allegro Ophthalmics, Allergan, BlephEx, Eyedetec, Glaukos, Guardion Health Sciences, Harvard Eye Associates, Harvard Hearing, Ingenoeye, MDbackline, Novartis, Ocular Therapeutix, Sarentis Ophthalmics, Sight Sciences, and Tear Film Innovations. Royalties: Slack Books and The Laser Center.
Preeya K. Gupta, MD, has had a financial agreement or affiliation with the following ineligible companies in the form of Consultant: Alcon, Aldeyra, Allergan, Azura, Carl Zeiss Meditec, Expert Opinion, HanAll Biopharma, Johnson & Johnson Vision, Kala Pharmaceuticals, New World Medical, Novartis, Ocular Science, Ocular Therapeutix, Orasis, Oyster Point, Sight Sciences, Spyglass, Surface Ophthalmics, Sun Pharmaceutical Industries, Tear Clear, TearLab, Tissue Tech, and Visionology. Stock/Shareholder: Azura, Expert Opinion, Orasis, Oyster Point, Tarsus, Tear Clear, Surface, Spyglass, Visionology, and Visant.
Mitch Ibach, OD, FAAO, has had a financial agreement or affiliation with the following ineligible companies in the form of Consultant: Aerie Pharmaceuticals, Alcon, Allergan, Avellino, Bausch + Lomb, Dompé, Gauch Health, Glaukos, Heru, Kala Pharmaceuticals, Ocular Therapeutix, Oyster Point, and Sight Sciences. Grant/Research Support: Ocular Therapeutix. Speakers’ Bureau: Aerie Pharmaceuticals, Dompé, Glaukos, Heru, Ocular Therapeutix, Oyster Point, Sight Sciences, and Sun Pharmaceutical Industries. Stock/Shareholder: Equinox.
The Evolve staff, planners, and reviewers have no financial relationships with ineligible companies.
OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Ocular Therapeutix.
Release Date:
Expiration Date:
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Marion Munk, MD, Ph.D
David Boyer, MD
Diana V. Do, MD
Marion Munk, MD, Ph.D
Diana V. Do, MD
David Boyer, MD
Janis T. Eells, Ph.D.
David Boyer, MD
Diana V. Do, MD
Marion Munk, MD, Ph.D
